WALSIH Virtual Global Expert Program: Chris Molloy

​​This session will discuss what support SME’s and service companies can benefit from in a changing investment and licensing market. These include agile access to new decision-making technologies and ‘Pharma-class’ R&D expertise. Also to the right services, in the right places at the right time.

​It will cover international R&D opportunities between Australia, UK and other nations supported by existing trade and regulatory alliances to speed up access to R&D services, trials, regulatory guidance and investment.

​The session will also discuss the impact on the sector of AI, Real World Clinical Evidence and a wide range of advanced therapeutics starting with Cell & Gene Therapies, but also radiopharmaceuticals, nanomedicines and targeted drug delivery that will shape a new generation of high-value precision medicines.